MET and renal cell carcinoma: Because cabozantinib is also used as a late-line therapy against TKI-resistant RCC, we investigated MET expression and the therapeutic effects of cabozantinib and HSF4 knockdown in sunitinib-resistant RCC previously studied in our department [9].